Mustang Bio, Inc. ROIC

ROIC of MBIO for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROIC growth rates and interactive chart. Return on invested capital (ROIC) is a calculation used to assess a company's efficiency at allocating the capital under its control to profitable investments. Calculated as Net Operating Profit After Tax or EBIT*(1-tax rate) divided by average invested capital. Invested capital is calculated as equity plus long-term and short-term debt minus cash and short-term investments. ROIC is often compared to the Weighted average cost of capital (WACC). If it's above it, it is said the company is creating value, if it's below it's destroying it. A company with after tax operating profit of $10 million and invested capital of $50 million will have a ROIC of 20%.


Highlights and Quick Summary

  • Annual ROIC for 2020 was -1241.82% (a 149.77% increase from previous year)
  • Annual ROIC for 2019 was -497.19% (a -40.81% decrease from previous year)
  • Annual ROIC for 2018 was -840.05% (a -Infinity% decrease from previous year)
  • Twelve month ROIC ending September 29, 2021 was -1228.15% (a 135.35% increase compared to previous quarter)
  • Twelve month trailing ROIC decreased by -1.1% year-over-year
Trailing ROIC for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
-1228.15% -521.84% -613.65% -1241.82%
Visit stockrow.com/MBIO for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROIC of Mustang Bio, Inc.

Most recent ROICof MBIO including historical data for past 10 years.

Interactive Chart of ROIC of Mustang Bio, Inc.

Mustang Bio, Inc. ROIC for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -1241.82%
2019 -497.19%
2018 -840.05%
2017 0.0%
2016 0.0%
2015 0.0%

Business Profile of Mustang Bio, Inc.

Sector: Healthcare
Industry: Biotechnology
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.